ProShare Advisors’s Lunai Bioworks LNAI Stock Holding History

ProShare Advisors’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-307	Closed	-$13.3K	–	2167
2025 Q1	$13.3K	Sell	307 -100	-25%	-$6.4K	﹤0.01%	2058
2024 Q4	$27.2K	Buy	+407	New	+$27K	﹤0.01%	2242

Other funds holding LNAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

ProShare Advisors's LNAI Position: Q2 2025 in Review

ProShare Advisors sold out of Lunai Bioworks (LNAI) in Q2 2025, closing a stake of 307 shares — an estimated $13.3K sold.

ProShare Advisors first reported a position in LNAI in Q4 2024 and held it in 2 quarters. The position peaked at $27.2K in Q4 2024. 42 funds tracked by Wall St. Rank hold LNAI as of Q2 2025.

ProShare Advisors reported no remaining Lunai Bioworks position as of Q2 2025 after selling out during the quarter.
ProShare Advisors sold 307 Lunai Bioworks shares in Q2 2025, an estimated $13.3K.
ProShare Advisors first reported a position in Lunai Bioworks in Q4 2024 and held it in 2 quarters.
ProShare Advisors's Lunai Bioworks position peaked at $27.2K in Q4 2024.
42 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.